<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00304187</url>
  </required_header>
  <id_info>
    <org_study_id>#4902</org_study_id>
    <secondary_id>R01MH042206-05</secondary_id>
    <secondary_id>DATR A2-AID</secondary_id>
    <nct_id>NCT00304187</nct_id>
  </id_info>
  <brief_title>Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa</brief_title>
  <official_title>Effects of Erythromycin on Binge Eating and GI Function in Bulimia Nervosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the effectiveness of the antibiotic erythromycin in enhancing
      gastrointestinal function and decreasing the frequency of binge eating in people with bulimia
      nervosa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bulimia nervosa (BN) is a serious eating disorder that is characterized by frequent
      uncontrolled eating binges. These binges are often followed by compensatory behavior,
      including the following: self-induced vomiting; misuse of laxatives, diuretics, enemas, or
      other medications to induce purging; fasting; or excessive exercise. If left untreated, BN
      can lead to many serious health issues: tooth decay; irregular menstruation; bowel damage;
      constipation; heart and kidney disease; intestinal damage; puffiness, especially in the face
      and fingers; increased hair growth on the face and body; and mineral imbalances in the body.
      Although there is significant existing knowledge about the characteristics and treatment of
      BN, more information is needed about gastrointestinal (GI) function and its effect on binge
      eating behavior. This study will determine the effectiveness of the antibiotic erythromycin
      in enhancing GI function and decreasing the frequency of binge eating in people with BN.

      Participants in this 8-week, double-blind study will first undergo gastric emptying and GI
      hormone release testing for 1 day. Within 1 week of completing these pre-treatment tests,
      participants will be randomly assigned to receive either erythromycin or placebo for 6 weeks.
      Upon medication assignment, participants will meet with a psychiatrist to receive their
      assigned medication. Participants will receive medication at weekly study visits. Medication
      dosage will be increased if symptoms do not improve, or decreased if adverse medication side
      effects are reported. A final day of gastric emptying and GI hormone release testing, as well
      as routine blood tests, will take place in Week 7, after 6 weeks of medication treatment.
      Participants' weight will be measured at Weeks 1, 4, and 7. Participants will also receive an
      EKG 1 week after each upward dosage adjustment. Patients will be informed of their medication
      assignment at the Week 7 study visit, and will be referred to a non-study clinician for
      further treatment.

      For information on related studies, please see NCT00308776 and NCT00307190.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Binge Frequency</measure>
    <time_frame>Measured at Week 7</time_frame>
    <description>Binge frequency wass assessed by patient diary. All patients were asked to keep a diary of the number of daily binge eating and vomiting episodes which was collected at each weekly visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastric Emptying Rate</measure>
    <time_frame>Measured at Week 7</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Bulimia Nervosa</condition>
  <condition>Eating Disorders</condition>
  <arm_group>
    <arm_group_label>Erythromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with Bulimia Nervosa will take erythromycin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take matched placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythromycin</intervention_name>
    <description>Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks</description>
    <arm_group_label>Erythromycin</arm_group_label>
    <other_name>E-mycin</other_name>
    <other_name>Eryc</other_name>
    <other_name>Ery-tab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 250 mg or 500 mg, three times a day for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>inactive substance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets criteria for bulimia nervosa

          -  Duration of illness is greater than 1 year

          -  Self-induces vomiting

          -  Weighs 80%-120 % of ideal weight

        Exclusion Criteria:

          -  Significant medical illness

          -  Current or lifetime history of schizophrenia, bipolar disorder, or other psychotic
             disorder, as defined by American Psychiatric Association criteria

          -  Moderate to severe depression, as defined by a score greater than 18 on the Hamilton
             Depression Scales

          -  Current diagnosis of organic mental disorder, factitious disorder, or malingering

          -  History of a personality disorder (e.g., schizotypal, borderline, or antisocial) that
             might interfere with assessment or compliance with the study procedures

          -  At risk for suicide

          -  Current psychotropic medications and current medications that affect GI function or
             that inhibit or induce cytochrome three A gene expression

          -  Currently pregnant, lactating, or planning to become pregnant

          -  Drug or alcohol abuse within the 3 months prior to study entry

          -  Abnormal EKG at baseline or 1 week following each upward dosage adjustment

          -  Anemia

          -  Known intolerance to erythromycin, or related antibiotics

          -  Abnormal results on liver function tests

          -  Electrolyte abnormalities
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>B. T. Walsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute at Columbia University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eating Disorders Clinic, New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2006</study_first_submitted>
  <study_first_submitted_qc>March 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2006</study_first_posted>
  <results_first_submitted>April 24, 2013</results_first_submitted>
  <results_first_submitted_qc>June 21, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 30, 2013</results_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Binge-Eating Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Bulimia</mesh_term>
    <mesh_term>Binge-Eating Disorder</mesh_term>
    <mesh_term>Bulimia Nervosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eating Disorders Research Clinic at New York State Psychiatric Institute</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Erythromycin</title>
          <description>Subjects with Bulimia Nervosa will take erythromycin.
Erythromycin : Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants will take matched placebo.
Placebo : Placebo, 250 mg or 500 mg, three times a day for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Erythromycin</title>
          <description>Subjects with Bulimia Nervosa will take erythromycin.
Erythromycin : Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will take matched placebo.
Placebo : Placebo, 250 mg or 500 mg, three times a day for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" spread="3"/>
                    <measurement group_id="B2" value="24" spread="3"/>
                    <measurement group_id="B3" value="24" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Binge Frequency</title>
        <description>Binge frequency wass assessed by patient diary. All patients were asked to keep a diary of the number of daily binge eating and vomiting episodes which was collected at each weekly visit.</description>
        <time_frame>Measured at Week 7</time_frame>
        <population>Participants for analysis included 13 patients in the erythromycin and 13 patients in the placebo group who completed at least 5 weeks of drug treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Erythromycin</title>
            <description>Subjects with Bulimia Nervosa will take erythromycin.
Erythromycin : Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will take matched placebo.
Placebo : Placebo, 250 mg or 500 mg, three times a day for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Binge Frequency</title>
          <description>Binge frequency wass assessed by patient diary. All patients were asked to keep a diary of the number of daily binge eating and vomiting episodes which was collected at each weekly visit.</description>
          <population>Participants for analysis included 13 patients in the erythromycin and 13 patients in the placebo group who completed at least 5 weeks of drug treatment.</population>
          <units>Binge Episodes/Week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" spread="8.7"/>
                    <measurement group_id="O2" value="11.3" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Gastric Emptying Rate</title>
        <time_frame>Measured at Week 7</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Erythromycin</title>
          <description>Subjects with Bulimia Nervosa will take erythromycin.
Erythromycin : Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants will take matched placebo.
Placebo : Placebo, 250 mg or 500 mg, three times a day for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael Devlin</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>212-543-5748</phone>
      <email>mjd5@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

